文献速递妇科

血清外泌体长链非编码RNA对卵巢上皮性癌诊断价值的初步研究

[Preliminary study on the diagnostic value of serum-derived exosomal lncRNA in epithelial ovarian cancer].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2022-01-01

该研究收集卵巢癌35例、良性卵巢肿瘤20例及健康妇女15例,分离血清外泌体并高通量测序筛选差异表达lncRNA,发现6个lncRNA在卵巢癌中差异表达且联合检测AUC达0.962,诊断效能高于单一指标。

要点

  • 高通量测序可有效筛选血清外泌体差异表达lncRNA。
  • 6个lncRNA单独诊断卵巢癌的AUC为0.722~0.805,具中等诊断价值。
  • 联合因子预测模型3的AUC为0.962,诊断效能高于单一lncRNA。

核心结论

  • 高通量测序技术是筛选血清外泌体差异表达lncRNA的有效方法,多个lncRNA联合检测对卵巢癌诊断效能高于单一lncRNA检测,可为卵巢癌诊断提供新思路。

研究设计与样本

  • 收集2018年8月至2019年12月在广西医科大学附属肿瘤医院住院的卵巢癌35例(恶性组)、卵巢良性肿瘤20例(良性组)及同期体检健康妇女15例(正常组)。
  • 随机抽取恶性组4例(恶性测序组)和正常组3例(正常测序组)行高通量测序,并在全部70份血清样本中行实时荧光定量PCR验证。
  • 绘制ROC曲线评价诊断效能,采用logistic二元回归构建多因子联合诊断模型。

主要发现

  • 透射电镜显示血清外泌体呈脂质双层膜结构,NanoSight检测粒径峰值为127.6 nm,30~150 nm颗粒占58.9%。
  • 与正常测序组(3例)相比,恶性测序组(4例)血清外泌体中筛选出差异表达lncRNA 425个,其中上调23个、下调402个。
  • 与良性组、正常组相比,恶性组FER1L6-AS2表达升高至1.66、1.84倍,LINC00470升高至2.05、2.46倍,LINC01811升高至2.94、2.35倍。
  • 与良性组、正常组相比,恶性组CXXC4-AS1表达下降至29%、34%,LINC02343下降至40%、46%,LINC02428下降至42%、42%。
  • 6个lncRNA单独诊断AUC为0.722~0.805,联合因子预测模型1、2、3的AUC分别为0.865、0.934、0.962。

关键数值与推荐

  • 同一lncRNA在恶性组与良性组、恶性组与正常组间比较,差异均有统计学意义(P均<0.05);良性组与正常组比较,差异均无统计学意义(P均>0.05)。
  • 各联合因子预测模型的诊断效能均显著高于单一lncRNA的诊断效能(P均<0.05)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the diagnostic value of long noncoding RNA (lncRNA) extracted from serum exosomes in epithelial ovarian cancer (EOC). Methods: (1) Patients with ovarian tumors who were hospitalized in the Affiliated Tumor Hospital of Guangxi Medical University from August 2018 to December 2019, including 35 cases of EOC patients (malignant group) and 20 cases of benign ovarian tumor patients (benign group) were collected; during the same period, 15 healthy women (normal group) who underwent physical examination in the Affiliated Tumor Hospital of Guangxi Medical University were used as controls. Fasting venous blood serum was collected from the above three groups of women, and serum exosomes were isolated and purified using commercial kits. The morphology of exosomal particles was observed with transmission electron microscope, and the particle size distribution of the exosomes was detected by NanoSight technology. The expression of specific proteins cluster of differentiation (CD)63, CD81, and tumor susceptibility gene 101 (TSG101) of exosomes were analyzed by western blot. (2) Four cases of EOC patients and three cases of healthy women were randomly selected. High-throughput sequencing technology was used to analyze the differentially expressed lncRNA in serum exosomes of these four EOC patients and three healthy women, and screen out the significantly differentially expressed lncRNA. The screened lncRNA with different expression levels was verified by quantitative reverse transcription-polymerase chain reaction (QRT-PCR) in these seven original clinical samples, furtherly confirmed and tested with QRT-PCR in larger clinical samples (a total of 70 serum samples). (3) The receiver operating characteristic (ROC) curve of the target lncRNA was drawn and its diagnostic indicators such as sensitivity and specificity were evaluated. By using logistic binary regression model, multi-factor joint diagnostic models were constructed and evaluated. Results: (1) Under transmission electron microscope, clear lipid bilayer structure was observed in serum exosomes, and one side presented a concave hemispheric or cup like structure; the peak diameter of the exosomal particles detected with NanoSight technology was 127.6 nm, and the particles between 30 and 150 nm accounted for 58.9%; western blot confirmed that the obtained (exosomal) particles could detect the expression of the marker proteins CD63, CD81, and TSG101. (2) Analysis of high-throughput sequencing technology showed that compared with the women in the normal sequencing group (3 cases), 425 differentially expressed lncRNAs (including 23 up-regulated and 402 down-regulated) were screened in the serum exosomes of the malignant sequencing group (4 cases). Six types of lncRNA with significantly abnormal expression levels (including FER1L6-AS2, LINC00470, LINC01811, CXXC4-AS1, LINC02343, and LINC02428) were randomly selected for original sample verification, and the results were consistent with the sequencing results. Subsequently, these six lncRNAs were used for larger samples QRT-PCR verification. Compared with the benign and normal groups, the expression of FER1L6-AS2, LINC00470 and LINC01811 in malignant group increased by 1.66 and 1.84-fold, 2.05 and 2.46-fold, 2.94 and 2.35-fold, respectively; the expressions of CXXC4-AS1, LINC02343 and LINC02428 were down-regulated to 29% and 34%, 40% and 46%, 42% and 42%, respectively. For the same lncRNA, there were statistical differences between the malignant group and the benign group, between the malignant group and the normal group (all P<0.05), and there were no statistical differences between the benign group and the normal group (all P>0.05). (3) The results showed that the area under curve (AUC) of these six lncRNAs ranged from 0.722 to 0.805, which had moderate diagnostic efficiency. To use logistic binary regression model to establish multi-indicator joint diagnostic models and establish different joint factor ROC curves. The results showed that the AUC of the joint factor prediction model 1 (composed of FER1L6-AS2 and LINC01811), the joint factor prediction model 2 (composed of CXXC4-AS1, LINC02343, and LINC02428), and the joint factor prediction model 3 (composed of FER1L6-AS2, CXXC4-AS1, LINC02343, and LINC02428) were 0.865, 0.934, and 0.962, respectively. The diagnostic efficacy of the combined factor prediction models was higher than that of the single lncRNA (all P<0.05). Conclusions: High-throughput sequencing technology is an effective method for screening out the different expression levels of lncRNA extracted from serum exosomes. The combined detection of multiple serum exosomal lncRNA indicators has a certain diagnostic efficacy for patients with EOC. Detection of serum exosomal lncRNA indicators will provide new ideas for the diagnosis of EOC. 目的: 初步探讨血清外泌体长链非编码RNA(lncRNA)对卵巢上皮性癌(卵巢癌)的诊断价值。 方法: (1)收集2018年8月至2019年12月在广西医科大学附属肿瘤医院住院治疗的卵巢肿瘤患者,包括卵巢癌35例(恶性组)和卵巢良性肿瘤20例(良性组);收集同期在本院体检的健康妇女15例(正常组)作为对照。抽取3组妇女的外周静脉血,采用商品试剂盒分离、纯化血清外泌体;外泌体的鉴定:透射电子显微镜观察外泌体的形态,NanoSight纳米颗粒分析技术分析外泌体的粒径分布,蛋白印迹(western blot)法检测外泌体的特异性标志蛋白分化群(CD)63、CD81、肿瘤易感基因101蛋白(TSG101)的表达情况。(2)随机抽取恶性组中4例卵巢癌患者(恶性测序组)和正常组中3例健康妇女(正常测序组),采用高通量测序技术分析两组妇女的血清外泌体差异表达的lncRNA,并筛选出差异表达明显的lncRNA;实时荧光定量PCR技术验证筛选出的差异表达lncRNA在恶性测序组和正常测序组妇女血清中的表达,进一步扩大样本量(即恶性组、良性组、正常组共70份血清)验证筛选出的差异表达lncRNA在其中的表达。(3)绘制筛选出的差异表达lncRNA诊断卵巢癌的受试者工作特征(ROC)曲线,评价其敏感度和特异度等诊断效能;构建多因子联合诊断模型,通过logistic回归模型结合ROC曲线,评价其对卵巢癌发生的诊断效能。 结果: (1)透射电子显微镜观察,血清外泌体为脂质双层膜结构,一侧呈凹陷的半球形或杯托样;NanoSight纳米颗粒分析技术分析显示,外泌体颗粒的直径峰值为127.6 nm,直径30~150 nm的外泌体颗粒占58.9%;western blot法检测显示,与卵巢癌细胞系SKOV3细胞相比,血清外泌体的特异性标志蛋白CD63、CD81、TSG101蛋白的表达强度明显增强。(2)高通量测序技术分析显示,相对于正常测序组妇女,恶性测序组患者血清外泌体中筛选出差异表达lncRNA 425个(其中上调23个、下调402个);挑选上调、下调表达异常明显的lncRNA 6个,即FER1L6-AS2、LINC00470、LINC01811、CXXC4-AS1、LINC02343、LINC02428,采用实时荧光定量PCR技术对恶性测序组和正常测序组妇女血清进行验证,其表达情况与测序结果一致。随后对这6个lncRNA进一步扩大样本量验证,恶性组患者血清外泌体中FER1L6-AS2、LINC00470、LINC01811的表达水平分别升高至良性组、正常组妇女的1.66、1.84倍,2.05、2.46倍,2.94、2.35倍,CXXC4-AS1、LINC02343、LINC02428的表达水平分别下降至良性组、正常组妇女的29%、34%,40%、46%,42%、42%,同一lncRNA的表达水平在恶性组与良性组、恶性组与正常组中分别比较,差异均有统计学意义(P均<0.05),而良性组与正常组分别比较,差异均无统计学意义(P均>0.05)。(3)6个差异表达lncRNA单独诊断卵巢癌的ROC曲线下面积(AUC)为0.722~0.805,具有中等诊断价值。联合因子预测模型1(包括FER1L6-AS2和LINC01811)、联合因子预测模型2(包括CXXC4-AS1、LINC02343和LINC02428)、联合因子预测模型3(包括FER1L6-AS2、CXXC4-AS1、LINC02343和LINC02428)的AUC分别为0.865、0.934和0.962,各联合因子预测模型的诊断效能均显著高于单一lncRNA的诊断效能(P均<0.05)。 结论: 经实时荧光定量PCR技术验证,高通量测序技术是筛选血清外泌体差异表达lncRNA的有效方法;血清外泌体多个lncRNA联合检测对卵巢癌患者的诊断效能显著高于单一lncRNA检测。检测血清外泌体lncRNA可为卵巢癌的诊断提供新的思路。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li YW, Li L. [Preliminary study on the diagnostic value of serum-derived exosomal lncRNA in epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi. 2022. PMID: 35385957. doi:10.3760/cma.j.cn112141-20220114-00022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。